Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Boghaert
Erwin Boghaert, Pleasant Prairie, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20120071350 | TUMOR-INITIATING CELLS AND METHODS FOR USING SAME - Isolated and enriched tumor-initiating cell populations, methods for preparing the same, and uses thereof. | 03-22-2012 |
Erwin R. Boghaert, Monroe, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100021483 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES - Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same. | 01-28-2010 |
| 20100173382 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES - Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same. | 07-08-2010 |
| 20120064600 | ANTI-5T4 ANTIBODIES AND USES THEREOF - Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same. | 03-15-2012 |
Erwin R. Boghaert, Pleasant Prairie, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20110117079 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 05-19-2011 |
Erwin Raymond Arsene Boghaert, Monroe, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20090105461 | Calicheamicin conjugates - Anti-Lewis Y antibodies are described. Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Specifically, monomeric calicheamicin derivative/anti-Lewis Y antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. | 04-23-2009 |